phenylephrine-hydrochloride and Bronchopulmonary-Dysplasia

Nasal continuous positive airway pressure (NCPAP) is an effective method of respiratory support for preterm infants. Nasal masks and binasal prongs are two interfaces available to deliver NCPAP, and it is unclear if one is superior to the other. We conducted a systematic review and meta-analysis, using the methodology recommended by the Cochrane Collaboration, to compare the efficacy and safety of nasal masks versus binasal prongs to deliver NCPAP in preterm infants <37 weeks of gestation. Ovid MEDLINE, Embase, Scopus, the Cochrane database, and PubMed were searched in February 2019. Seven trials met the inclusion criteria. Among preterm infants requiring NCPAP, the use of a nasal mask, compared to nasal prongs, decreased the rate of NCPAP failure within 72 h (RR 0.72, 95% CI 0.53-0.97; number needed to treat for an additional beneficial outcome [NNTB] 12.5, 95% CI 7.1-100; 5 trials, 576 participants; low-certainty evidence) and the incidence of nasal injury (RR 0.71, 95% CI 0.59-0.85; NNTB 8.3, 95% CI 5.6-16.7; 6 trials, 665 participants; low-certainty evidence). In a subgroup of preterm infants requiring NCPAP after resuscitation at birth, the use of a nasal mask decreased the incidence of moderate-to-severe bronchopulmonary dysplasia (RR 0.47, 95% CI 0.23-0.95; NNTB 16.7, 95% CI 9.1-100; 4 trials, 395 participants; very-low-certainty evidence) and the need for subsequent surfactant administration (RR 0.78, 95% CI 0.64-0.96; NNTB 8.33, 95% CI 4.54-33.33; 4 trials, 395 participants; low-certainty evidence). The use of nasal masks for preterm infants requiring NCPAP was associated with a reduction in NCPAP failure, need for surfactant administration, and moderate-to-severe bronchopulmonary dysplasia (low- to very-low-certainty evidence). Given the potential clinical benefit and minimal risk associated with a change in patient interface, nasal masks should be considered the preferred interface for NCPAP delivery in preterm infants.

Topics: Bronchopulmonary Dysplasia; Continuous Positive Airway Pressure; Humans; Incidence; Infant, Newborn; Infant, Premature; Masks; Nose; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome, Newborn

Continuous positive airway pressure (CPAP) was introduced in 1971 and at that time welcomed as 'the missing link' between oxygen and ventilator treatment of premature infants. Originally CPAP was administered by tracheal tube (or head box) which because of the inherent risk of complications necessitated a cautious approach. New, more simple and less risky methods of application, such as nasal CPAP (N-CPAP), permitted earlier treatment which in randomized trials showed a reduction in inspired oxygen concentration, reduced need for mechanical ventilation and a reduction in the rate of death. Early N-CPAP/minimal handling today is an established first-line treatment in a number of centers in Denmark and Sweden, while N-CPAP outside Scandinavia apparently is used less often. However, recently the method has gained new interest as more publications have demonstrated that N-CPAP/minimal handling is both feasible and effective in most very-low-birth-weight infants. Early rescue treatment with fast-acting surfactant, given during a brief intubation, has increased the effectiveness of N-CPAP further. Descriptive studies on N-CPAP suggest that the risk of bronchopulmonary dysplasia may be lower than in conventional intensive treatment because of the relatively low need for mechanical ventilation. This question is at the present time being addressed in a randomized controlled trial in England.

Topics: Bronchopulmonary Dysplasia; Humans; Infant, Newborn; Infant, Very Low Birth Weight; Intensive Care, Neonatal; Nose; Positive-Pressure Respiration; Pulmonary Surfactants; Respiratory Distress Syndrome, Newborn; Risk Factors

Topics: Bronchopulmonary Dysplasia; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Intubation, Intratracheal; Nose; Respiration, Artificial

Genital herpes, usually caused by herpes simplex virus type 2 (HSV-2), is one of the most common sexually transmitted diseases in humans. By contrast, intrauterine HSV-2 infections have been described rarely in the literature. Our report describes a case of neonate who was delivered after 30+2 gestational weeks by cesarean section. He presented with a respiratory distress syndrome resulting in broncho-pulmonary dysplasia. At the age of 6 weeks, a chorioretinal scar was detected. During the 4th month of age, the infant developed recurrent HSV-2 infection with nasal lesions. The retrospective type-specific serologic diagnosis revealed previous HSV-2 infection of the mother resulting in prenatal HSV-2 infection of the infant. In conclusion, intrauterine HSV-2 infections may be underrepresented since they may not be associated with severe congenital malformations and the diagnosis requires the use of HSV type-specific serologic methods not widely applied in microbiological laboratories.

Topics: Antibodies, Viral; Bronchopulmonary Dysplasia; Chorioretinitis; Female; Herpes Simplex; Herpesvirus 2, Human; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nose; Pregnancy; Respiratory Distress Syndrome, Newborn; Serotyping

Early nasal continuous positive airway pressure (nCPAP) or early surfactant therapy with early extubation onto nCPAP rather than continued mechanical ventilation has been adopted by many centres, particularly in Scandinavia, as part of the treatment of newborns with respiratory distress syndrome. It has been suggested that bronchopulmonary dysplasia is less of a problem in centres adopting such a policy. Results from randomized trials suggest prophylactic or early nCPAP may reduce bronchopulmonary dysplasia (BPD), but further studies are required to determine the relative contributions of an early lung recruitment policy, early surfactant administration and nCPAP in reducing BPD. In addition, the optimum method of generating and delivering CPAP needs to be determined.. The efficacy of nCPAP in improving long-term respiratory outcomes needs to be compared with the newer ventilator techniques with the optimum and timing of delivery of surfactant administration.

Topics: Bronchopulmonary Dysplasia; Continuous Positive Airway Pressure; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Nose; Pregnancy; Pregnancy Complications; Surface-Active Agents

The objective of this study was to evaluate the incidence of bronchopulmonary dysplasia (BPD), nutritional intake, and growth in premature infants receiving synchronized nasal intermittent positive-pressure ventilation (SNIPPV) versus nasal continuous positive airways pressure (NCPAP) after extubation, at an institution with no prior experience with SNIPPV. This was a retrospective case-control study of infants (born May 2000 to December 2003) at < or = 32 weeks gestation. Extubation to SNIPPV was performed in accordance with a standardized protocol. Infants in the control group were extubated to NCPAP, as per standard nursery practice. There were no significant differences in the maternal characteristics, antenatal corticosteroid use, mode of delivery, gestational age, birthweight, male gender, Apgar scores at 1 and 5 minutes, number of surfactant doses, and duration of endotracheal tube PPV between infants in the control group (n = 30) and those extubated to SNIPPV (n = 30). The duration of NCPAP (median [range]: control versus SNIPPV, 601 [24 to 1270] versus 230.5 [36 to 1200] hours; P < 0.001) and supplemental oxygen (mean +/- standard error of the mean: 84.10 +/- 6.43 versus 63.68 +/- 5.34 days; p = 0.02) was significantly lower in the SNIPPV group. The number of infants with BPD was significantly less in the SNIPPV group (73% versus 40%; p < 0.01). There were no differences between the two groups in total days on parenteral nutrition, caloric intake (total, carbohydrate, protein, or fat), or weight gain. Our results show that introduction of SNIPPV in a neonatal intensive care unit resulted in infants having significantly less need for supplemental oxygen and decreased BPD, without affecting their weight gain or the incidence of other short-term morbidities.

Topics: Adult; Bronchopulmonary Dysplasia; Case-Control Studies; Chronic Disease; Energy Intake; Female; Humans; Incidence; Infant; Infant Nutritional Physiological Phenomena; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Intensive Care, Neonatal; Intermittent Positive-Pressure Breathing; Male; Maternal Age; Nose; Oxygen Inhalation Therapy; Retrospective Studies; Treatment Outcome